The heart failure drug Natrecor (nesiritide) is ineffective and linked to increased rates of potentially dangerous low blood pressure, a new study finds. The intravenous drug was approved in 2001 to help heart failure patients breathe more easily when they were struggling with severe shortness of breath. But the drug had no significant effect on breathing difficulties or other disease-related problems and may also result in low blood pressure, according to the researchers. The report was published in the July 7 issue of the New England Journal of Medicine.
